PROVECTUS BIOPHARMACEUTICALS, INC. Annual Operating Lease, Payments in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
Summary
Provectus Biopharmaceuticals, Inc. quarterly/annual Operating Lease, Payments history and growth rate from 2019 to 2023.
  • Provectus Biopharmaceuticals, Inc. Operating Lease, Payments for the quarter ending March 31, 2024 was $11.6K, a 8.36% increase year-over-year.
  • Provectus Biopharmaceuticals, Inc. annual Operating Lease, Payments for 2023 was $44.4K, a 29.4% decline from 2022.
  • Provectus Biopharmaceuticals, Inc. annual Operating Lease, Payments for 2022 was $62.9K, a 23.9% decline from 2021.
  • Provectus Biopharmaceuticals, Inc. annual Operating Lease, Payments for 2021 was $82.7K, a 9.75% decline from 2020.
Operating Lease, Payments, Annual (USD)
Operating Lease, Payments, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $44.4K -$18.5K -29.4% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-28
2022 $62.9K -$19.7K -23.9% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-28
2021 $82.7K -$8.93K -9.75% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-30
2020 $91.6K +$2.03K +2.27% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-29
2019 $89.6K Jan 1, 2019 Dec 31, 2019 10-K 2021-03-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.